What we're tracking right now.
Recent WeighedHealth coverage: FDA decisions, recalls, GLP-1 shortage updates, legislation tracking, and editorial deep-dives.
Trackers
Recall & safety coverage
All recalls →ProRx LLC recalls compounded semaglutide and tirzepatide (October 2025)
In October 2025, compounder ProRx LLC initiated a voluntary nationwide recall of lots of its compounded semaglutide and tirzepatide injectable products due to lack of sterility assurance identified during inspection. Recalled lots and distribution details are listed in the FDA Enforcement Report database. Non-sterile injectables carry a risk of injection-site and bloodstream infections. Patients with affected lots were instructed to stop use and contact their dispensing pharmacy; no confirmed patient harm had been reported at announcement.
FDA warning letters to GLP-1 compounders and sellers, September 2025
With the tirzepatide shortage declared resolved in December 2024 and the semaglutide shortage in February 2025, the legal basis for routinely compounding "essentially a copy" of those drugs ended. In September 2025 the FDA announced a wave of warning letters to companies that continued compounding GLP-1 products or marketing unapproved GLP-1 drugs — citing violations of compounding rules, sourcing of semaglutide salt forms not permitted for compounding, and misleading marketing claims about equivalence to the approved products. Many recipients discontinued GLP-1 compounding; enforcement against non-compliant sellers has continued into 2026. Individual letters are published in the FDA's warning-letters database.
FDA declares semaglutide injection shortage resolved (February 2025)
On February 21, 2025 the FDA announced its determination that the shortage of semaglutide injection products (Wegovy and Ozempic) was resolved, with Novo Nordisk able to meet current and projected US demand. Because compounding of "essentially a copy" of an FDA-approved drug is only permitted during a shortage, the determination started a wind-down period for compounded semaglutide: 503A compounding pharmacies were given until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop producing it. Telehealth services that had offered compounded semaglutide during the shortage transitioned patients to branded Wegovy/Ozempic or alternative therapies.
FDA alert: counterfeit Ozempic pens found in US supply chain
On December 21, 2023 the FDA alerted patients, pharmacies, and wholesalers that counterfeit Ozempic (semaglutide) 1 mg pens had entered the US drug-supply chain outside authorized channels. The counterfeit products carry lot number NAR0074 with serial number 430834149057. FDA and Novo Nordisk seized thousands of units and advised that the pen needles in the counterfeit kits are themselves counterfeit, so their sterility cannot be assured. FDA reported a small number of adverse-event reports associated with the lot, none serious and consistent with known GI side effects of semaglutide. Wholesalers, pharmacies, and patients were told not to distribute, dispense, or use pens labeled with that lot/serial combination.
Latest articles
All articles →- glp1
Modern Fertility AMH testing: what 95th vs 5th percentile means (2026)
An AMH result at the 5th percentile doesn't mean infertility, and a result at the 95th percentile doesn't mean abundant fertility. Here's what the test actually measures and what high or low values predict.
- glp1
Ozempic for PCOS: off-label evidence 2026 review
Semaglutide is being prescribed off-label for PCOS more often each year. Here's what the published trials actually show on weight, ovulation, insulin resistance, and androgen levels — and what they don't.
- glp1
Wegovy prior authorization: the step-by-step approval playbook (2026)
Wegovy denials usually come from incomplete documentation, not clinical ineligibility. Here's the exact step-by-step process that gets approval on the first submission, plus what to do when denied.
- glp1
GLP-1 hair loss timeline: when it starts, peaks, and recovers (2026)
Hair shedding on Wegovy, Ozempic, or Zepbound follows a predictable pattern tied to rapid weight loss, not the drug itself. Here's the week-by-week timeline, why it happens, and what actually shortens recovery.
- glp1
Wegovy vs Ozempic in 2026: same drug, different prescribing rules
Wegovy and Ozempic are both semaglutide. Wegovy is FDA-approved for weight management; Ozempic for type 2 diabetes. Same active ingredient — but different dose, different insurance pathway, different cost, and different clinical conversation. Here's the full comparison.
- glp1
Mounjaro vs Zepbound (2026): tirzepatide split by indication
Mounjaro and Zepbound are both tirzepatide — Eli Lilly's dual GLP-1/GIP agonist. Mounjaro is FDA-approved for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity. Here's the regulatory split, dose ladder, insurance reality, and how to switch.
- glp1
Wegovy cost without insurance in 2026: cheapest legitimate paths
Wegovy's pharmacy list price is ~$1,349 per month. For uninsured patients, the cheapest legitimate paths in 2026 are NovoCare self-pay at $499/month, transitioning to oral orforglipron at $149/month when prescriber agrees, or compounded semaglutide (a narrowing legal grey zone). Here are the actual options and what's changing.
- glp1
Wegovy weight loss timeline: week-by-week expectations (2026)
Wegovy doesn't drop the scale immediately. Most patients lose 1-2 pounds in weeks 1-4, hit a 5% loss around month 4, reach 10% by month 8, and approach 15% by week 68. Here's what to actually expect, what's normal during titration, and when to call your prescriber if results lag.
- glp1
Ozempic injection sites and technique: complete how-to (2026)
Ozempic is injected once weekly under the skin (subcutaneous) of your abdomen, thigh, or upper arm. Site rotation matters — repeated injection in one spot causes lipohypertrophy that reduces drug absorption. Here's the full technique, site rotation schedule, what to avoid, and how to troubleshoot common problems.
- glp1
Foods to avoid on GLP-1 medications (Wegovy, Ozempic, Zepbound, Mounjaro) in 2026
GLP-1 medications slow gastric emptying — foods that already sit heavy in the stomach (fried, high-fat, fibrous) become much worse. Sulfur-rich foods (eggs, alliums, cruciferous) trigger sulfur burps. Alcohol, carbonated drinks, and spicy foods worsen nausea. Here's the complete avoidance + substitution guide.
- glp1
GLP-1 medications and alcohol in 2026: what to know
GLP-1 medications (Wegovy, Ozempic, Zepbound, Mounjaro) are not FDA-contraindicated with alcohol, but most patients find alcohol tolerance significantly reduced. Slowed gastric emptying means the same drink hits harder and later. Many patients lose interest in alcohol entirely. Here's the science, the practical limits, and the situations to avoid.
- glp1
Wegovy vs Ozempic side effects in 2026: complete comparison
Wegovy and Ozempic are both semaglutide so the side-effect profile is nearly identical: nausea, constipation, diarrhea, vomiting, fatigue. Differences exist primarily because Wegovy goes to a higher max dose (2.4mg vs 2.0mg), which means slightly more frequent and severe GI side effects. Here's the head-to-head data, what to expect, and how to manage.
Press inquiries: [email protected] · Press kit · RSS feed